NCT01625897 - A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia | Biotech Hunter

Enrollment

125

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Schizophrenia

Interventions

DRUG

MP-214

Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg or 6mg) of MP-214 for four weeks, then flexible dose (1.5-9mg) of MP-214

DRUG

Risperidone

Patients who meet eligibility criteria will be administered a once daily oral fixed dose (4mg) of risperidone for two weeks, then flexible dose (2-12mg) of risperidone

Trial Locations (1)

Unknown

Aizu-Wakamatsu